About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
ecancer
ecancer.org
ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.
ELCC 2024
EAU 2024
ASCO GU 2024
ASCO GI 2024
AORTIC 2023
ASH 2023
SABCS 2023
ESMO 2023
Common Sense Oncology
WCLC 2023
ESMO WCGIC 2023
ASCO® 2023
EHA® 2023
ELCC 2023
ASCO GU 2023
BGICC 2023
ASCO GI 2023
SABCS 2022
ESMO 2022
WCLC 2022
EHA 2022
ASCO 2022
ASCO 2021
Lymphoma
Leukemia
Myeloma
GYN Cancers
Head&Neck Cancers
GI Cancers
Breast Cancers
GU Cancers
Lung Cancers
Skin Cancers
Basic Science
Supportive & Palliative Care
Business
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
ASCO 2021 Update on IO in NSCLC: Considering Data From the Key Trials
By
ecancer
FEATURING
Luis Raez
By
ecancer
FEATURING
Luis Raez
60 views
September 2, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
23:46
AstraZeneca Oncology
First-line Maintenance Treatment Option in Patients With HRD-Positiv…
Feat.
S. Lewin
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
ASCO 2021
09:04
ecancer
2021 ASCO Update on Pancreatic and Hepatobiliary Cancers: Surveying …
Feat.
C. Lima
07:25
ecancer
ASCO 2021 Update on IO in NSCLC: Considering Data From the Key Trials
Feat.
L. Raez
09:55
ecancer
ASCO 2021 Update on Oncogenesis in NSCLC: Overview of Targeting Path…
Feat.
E. Santos
06:24
ecancer
ASCO 2021 Update on mCRPC: VISION Trial Data on Lutetium-177-PSMA-617
Feat.
M. Morris
06:47
ecancer
2021 ASCO Highlights on the Most Recent MDS Trials
Feat.
F. Vargas
06:20
ecancer
ASCO 2021 Data on Adjuvant Olaparib for Patients with BRCA1/2-Mutate…
Feat.
Z. Nahleh
05:38
ecancer
ASCO 2021 Update on Targeted Therapy in BC: Surveying Data From Key …
Feat.
A. Castrellon
09:26
ecancer
2021 ASCO Update From ELARA Study on Adult Patients With R/R FL: Eff…
Feat.
S. Schuster
28:03
ecancer
ASCO 2021 Updates From Noteworthy Studies: GYN, H&N, GU, Breast,…
Feat.
B. Gyawali
05:27
ecancer
ASCO 2021 Update on Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibit…
Feat.
C. Baik
05:50
ecancer
ASCO 2021 Update on RAS Wild-Type mCRC: PANAMA Trial Data on Mainten…
Feat.
D. Modest
07:47
ecancer
Tislelizumab vs. Chemo in 2L for Advanced ESCC: RATIONALE-302 Safety…
Feat.
J. Ajani
05:20
ecancer
ASCO 2021 Update on Pembrolizumab vs. Chemo in MSI-H/dMMR mCRC: Fina…
Feat.
T. André
08:48
ecancer
2021 ASCO Update on CROSS vs. Perioperative Chemo in Esophagus and G…
Feat.
J. Reynolds
14:47
ecancer
2021 ASCO Updates on FGFR as a Tumour Agnostic Indicator and Its Imp…
Feat.
C. Massard,
E. Comperat
25:53
ecancer
2021 ASCO Data on mHSPC: Overview of the Most Important Trials
Feat.
K. Fizazi,
N. Agarwal,
A. Morgans,
L. Krabbe
05:32
ecancer
ASCO 2021 RCC Roundup: Surveying Data From the Key Studies
Feat.
B. McGregor
27:02
ecancer
2021 ASCO Highlights on mCRPC: Latest Developments in Diagnostics &a…
Feat.
E. Efstathiou,
O. Sartor,
F. Saad
17:44
ecancer
ASCO 2021 Highlights on PARPi and Other mCRPC Treatments
Feat.
N. Shore,
O. Sartor
06:50
ecancer
ASCO 2021 Update on Abiraterone Acetate + Prednisone and/or Local RT…
Feat.
K. Fizazi
07:24
ecancer
2021 ASCO Update in MIBC Patients: HCRN GU 16-257 Trial Data on Gemc…
Feat.
M. Galsky
09:48
ecancer
ASCO 2021 Update on Newly Diagnosed mHSPC: ADT + TAK-700 With ADT + …
Feat.
N. Agarwal
18:13
ecancer
ASCO 2021 Update on Precision and Molecular Reporting for mCRPC: Rad…
Feat.
E. Efstathiou
08:55
ecancer
ASCO 2021 Data on Acalabrutinib +/- Obinutuzumab vs. Obinutuzumab + …
Feat.
J. Sharman
08:09
ecancer
ASCO 2021 Update on Adjuvant Olaparib in High-Risk HER2- EBC With BR…
Feat.
A. Tutt
06:33
ecancer
Clinically Sufficient Vitamin D Levels at BC Diagnosis & Surviva…
Feat.
S. Yao
16:44
ecancer
ASCO 2021 Breast Cancer Roundup on Early & Advanced Setting of B…
Feat.
M. Lambertini
05:33
ecancer
2021 ASCO Review on KEYNOTE-564: Pembro vs. Placebo as Post-Nephrect…
Feat.
T. Choueiri
07:23
ecancer
2021 ASCO Review on Nivo + Chemo vs. Chemo Alone as Neoadjuvant Trea…
Feat.
J. Spicer
16:37
ecancer
2021 ASCO Highlights on Amivantamab + Lazertinib for Osimertinib-Rel…
Feat.
J. Sabari,
A. Minchom
06:05
ecancer
2021 ASCO Updates on LEAP-004: Lenvatinib + Pembro for Patients with…
Feat.
A. Arance
37:25
ecancer
2021 ASCO Updates in Exon 20 Insertions: Targeted Therapies, Novel A…
Feat.
M. Krebs,
S. Viteri,
S. Gadgeel,
B. Chul Cho
08:57
ecancer
2021 ASCO Updates on Neoadjuvant IO in NSCLC
Feat.
L. Raez
